JP2011521963A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011521963A5 JP2011521963A5 JP2011511820A JP2011511820A JP2011521963A5 JP 2011521963 A5 JP2011521963 A5 JP 2011521963A5 JP 2011511820 A JP2011511820 A JP 2011511820A JP 2011511820 A JP2011511820 A JP 2011511820A JP 2011521963 A5 JP2011521963 A5 JP 2011521963A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- halogen
- phenyl
- haloalkyl
- cycloalkylalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 72
- 229910052736 halogen Inorganic materials 0.000 claims description 72
- 150000002367 halogens Chemical class 0.000 claims description 71
- 150000001875 compounds Chemical class 0.000 claims description 63
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 60
- 125000000217 alkyl group Chemical group 0.000 claims description 59
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims description 58
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims description 56
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 50
- XTFIVUDBNACUBN-UHFFFAOYSA-N 1,3,5-trinitro-1,3,5-triazinane Chemical compound [O-][N+](=O)N1CN([N+]([O-])=O)CN([N+]([O-])=O)C1 XTFIVUDBNACUBN-UHFFFAOYSA-N 0.000 claims description 50
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 50
- -1 saturated bicyclic heterocyclic amine Chemical group 0.000 claims description 42
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 36
- 125000001424 substituent group Chemical group 0.000 claims description 33
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 32
- 125000003118 aryl group Chemical group 0.000 claims description 32
- 125000001072 heteroaryl group Chemical group 0.000 claims description 32
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 23
- 239000008194 pharmaceutical composition Substances 0.000 claims description 22
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 21
- 125000003545 alkoxy group Chemical group 0.000 claims description 20
- 150000003839 salts Chemical class 0.000 claims description 14
- 229910052757 nitrogen Inorganic materials 0.000 claims description 12
- UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical compound [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 claims description 12
- 229940076279 serotonin Drugs 0.000 claims description 12
- 125000000304 alkynyl group Chemical group 0.000 claims description 11
- 208000018737 Parkinson disease Diseases 0.000 claims description 10
- 150000001408 amides Chemical class 0.000 claims description 10
- 201000000980 schizophrenia Diseases 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 229940075993 receptor modulator Drugs 0.000 claims description 9
- 239000002671 adjuvant Substances 0.000 claims description 8
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 claims description 8
- 208000031649 Postoperative Nausea and Vomiting Diseases 0.000 claims description 7
- 150000001412 amines Chemical class 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 206010047700 Vomiting Diseases 0.000 claims description 5
- 208000015114 central nervous system disease Diseases 0.000 claims description 5
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 5
- 102000005962 receptors Human genes 0.000 claims description 5
- 108020003175 receptors Proteins 0.000 claims description 5
- 230000008673 vomiting Effects 0.000 claims description 5
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- 206010028817 Nausea and vomiting symptoms Diseases 0.000 claims description 4
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 claims description 4
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 claims description 4
- 229960004538 alprazolam Drugs 0.000 claims description 4
- 238000010976 amide bond formation reaction Methods 0.000 claims description 4
- 230000003474 anti-emetic effect Effects 0.000 claims description 4
- 239000002111 antiemetic agent Substances 0.000 claims description 4
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 claims description 4
- 229960004242 dronabinol Drugs 0.000 claims description 4
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims description 4
- 229960003878 haloperidol Drugs 0.000 claims description 4
- 150000002500 ions Chemical class 0.000 claims description 4
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 claims description 4
- 229960005017 olanzapine Drugs 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 claims description 3
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 claims description 3
- 239000000812 cholinergic antagonist Substances 0.000 claims description 3
- 208000035475 disorder Diseases 0.000 claims description 3
- 230000000694 effects Effects 0.000 claims description 3
- MFWNKCLOYSRHCJ-BTTYYORXSA-N granisetron Chemical compound C1=CC=C2C(C(=O)N[C@H]3C[C@H]4CCC[C@@H](C3)N4C)=NN(C)C2=C1 MFWNKCLOYSRHCJ-BTTYYORXSA-N 0.000 claims description 3
- 229960003727 granisetron Drugs 0.000 claims description 3
- 229960005343 ondansetron Drugs 0.000 claims description 3
- 229960002131 palonosetron Drugs 0.000 claims description 3
- CPZBLNMUGSZIPR-NVXWUHKLSA-N palonosetron Chemical compound C1N(CC2)CCC2[C@@H]1N1C(=O)C(C=CC=C2CCC3)=C2[C@H]3C1 CPZBLNMUGSZIPR-NVXWUHKLSA-N 0.000 claims description 3
- DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 claims description 2
- UUAVYXKRUSVCDJ-UHFFFAOYSA-N 1-cycloheptylazepane Chemical group C1CCCCCC1N1CCCCCC1 UUAVYXKRUSVCDJ-UHFFFAOYSA-N 0.000 claims description 2
- ULFNAOHBWGRYLW-UHFFFAOYSA-N 1-cyclononylazonane Chemical group C1CCCCCCCC1N1CCCCCCCC1 ULFNAOHBWGRYLW-UHFFFAOYSA-N 0.000 claims description 2
- QUIJMHDIAFOPRK-UHFFFAOYSA-N 1-cyclooctylazocane Chemical group C1CCCCCCC1N1CCCCCCC1 QUIJMHDIAFOPRK-UHFFFAOYSA-N 0.000 claims description 2
- PMXMIIMHBWHSKN-UHFFFAOYSA-N 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCC(O)C4=NC=3C)=NOC2=C1 PMXMIIMHBWHSKN-UHFFFAOYSA-N 0.000 claims description 2
- XLRPYZSEQKXZAA-UHFFFAOYSA-N 8-methyl-8-azabicyclo[3.2.1]octane Chemical compound C1CCC2CCC1N2C XLRPYZSEQKXZAA-UHFFFAOYSA-N 0.000 claims description 2
- ODWVFJUVKLPMDM-UHFFFAOYSA-N 9-methyl-9-azabicyclo[3.3.1]nonane Chemical compound C1CCC2CCCC1N2C ODWVFJUVKLPMDM-UHFFFAOYSA-N 0.000 claims description 2
- 208000007848 Alcoholism Diseases 0.000 claims description 2
- 208000019901 Anxiety disease Diseases 0.000 claims description 2
- 206010006550 Bulimia nervosa Diseases 0.000 claims description 2
- 208000011691 Burkitt lymphomas Diseases 0.000 claims description 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 2
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims description 2
- 206010012289 Dementia Diseases 0.000 claims description 2
- CYQFCXCEBYINGO-DLBZAZTESA-N Dronabinol Natural products C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@H]21 CYQFCXCEBYINGO-DLBZAZTESA-N 0.000 claims description 2
- 208000001640 Fibromyalgia Diseases 0.000 claims description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 2
- 208000023105 Huntington disease Diseases 0.000 claims description 2
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 claims description 2
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims description 2
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims description 2
- 208000019695 Migraine disease Diseases 0.000 claims description 2
- 102000010909 Monoamine Oxidase Human genes 0.000 claims description 2
- 108010062431 Monoamine oxidase Proteins 0.000 claims description 2
- 208000008589 Obesity Diseases 0.000 claims description 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 2
- 208000002193 Pain Diseases 0.000 claims description 2
- 206010036631 Presenile dementia Diseases 0.000 claims description 2
- 206010066962 Procedural nausea Diseases 0.000 claims description 2
- 206010066963 Procedural vomiting Diseases 0.000 claims description 2
- 208000003251 Pruritus Diseases 0.000 claims description 2
- 208000028017 Psychotic disease Diseases 0.000 claims description 2
- 241001303601 Rosacea Species 0.000 claims description 2
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 claims description 2
- 206010041247 Social fear Diseases 0.000 claims description 2
- 229940123445 Tricyclic antidepressant Drugs 0.000 claims description 2
- 201000007930 alcohol dependence Diseases 0.000 claims description 2
- 229960003550 alosetron Drugs 0.000 claims description 2
- FLZQKRKHLSUHOR-UHFFFAOYSA-N alosetron Chemical compound CC1=NC=N[C]1CN1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FLZQKRKHLSUHOR-UHFFFAOYSA-N 0.000 claims description 2
- 229960003805 amantadine Drugs 0.000 claims description 2
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 claims description 2
- 230000003444 anaesthetic effect Effects 0.000 claims description 2
- 239000005557 antagonist Substances 0.000 claims description 2
- 230000001430 anti-depressive effect Effects 0.000 claims description 2
- 230000002921 anti-spasmodic effect Effects 0.000 claims description 2
- 239000000935 antidepressant agent Substances 0.000 claims description 2
- 229940005513 antidepressants Drugs 0.000 claims description 2
- 239000003793 antidiarrheal agent Substances 0.000 claims description 2
- 229940125714 antidiarrheal agent Drugs 0.000 claims description 2
- ATALOFNDEOCMKK-OITMNORJSA-N aprepitant Chemical compound O([C@@H]([C@@H]1C=2C=CC(F)=CC=2)O[C@H](C)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)CCN1CC1=NNC(=O)N1 ATALOFNDEOCMKK-OITMNORJSA-N 0.000 claims description 2
- 229960001372 aprepitant Drugs 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 claims description 2
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 claims description 2
- 229960000623 carbamazepine Drugs 0.000 claims description 2
- 229960004205 carbidopa Drugs 0.000 claims description 2
- TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 claims description 2
- 239000003543 catechol methyltransferase inhibitor Substances 0.000 claims description 2
- UKTAZPQNNNJVKR-KJGYPYNMSA-N chembl2368925 Chemical compound C1=CC=C2C(C(O[C@@H]3C[C@@H]4C[C@H]5C[C@@H](N4CC5=O)C3)=O)=CNC2=C1 UKTAZPQNNNJVKR-KJGYPYNMSA-N 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 238000002512 chemotherapy Methods 0.000 claims description 2
- 229960004170 clozapine Drugs 0.000 claims description 2
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 claims description 2
- 230000007278 cognition impairment Effects 0.000 claims description 2
- 230000006999 cognitive decline Effects 0.000 claims description 2
- 208000010877 cognitive disease Diseases 0.000 claims description 2
- 230000007812 deficiency Effects 0.000 claims description 2
- 229960003957 dexamethasone Drugs 0.000 claims description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 2
- 229960003529 diazepam Drugs 0.000 claims description 2
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 claims description 2
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 claims description 2
- 229960000520 diphenhydramine Drugs 0.000 claims description 2
- 208000002173 dizziness Diseases 0.000 claims description 2
- 229960003413 dolasetron Drugs 0.000 claims description 2
- 239000003136 dopamine receptor stimulating agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 206010015037 epilepsy Diseases 0.000 claims description 2
- 230000005176 gastrointestinal motility Effects 0.000 claims description 2
- 208000030603 inherited susceptibility to asthma Diseases 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- 239000008141 laxative Substances 0.000 claims description 2
- 230000002475 laxative effect Effects 0.000 claims description 2
- 229960004502 levodopa Drugs 0.000 claims description 2
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 claims description 2
- 229910052808 lithium carbonate Inorganic materials 0.000 claims description 2
- 229940008015 lithium carbonate Drugs 0.000 claims description 2
- 229960004391 lorazepam Drugs 0.000 claims description 2
- 230000001404 mediated effect Effects 0.000 claims description 2
- 229940042053 methotrimeprazine Drugs 0.000 claims description 2
- VRQVVMDWGGWHTJ-CQSZACIVSA-N methotrimeprazine Chemical compound C1=CC=C2N(C[C@H](C)CN(C)C)C3=CC(OC)=CC=C3SC2=C1 VRQVVMDWGGWHTJ-CQSZACIVSA-N 0.000 claims description 2
- TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 claims description 2
- 229960004503 metoclopramide Drugs 0.000 claims description 2
- 229960003793 midazolam Drugs 0.000 claims description 2
- DDLIGBOFAVUZHB-UHFFFAOYSA-N midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 claims description 2
- 206010027599 migraine Diseases 0.000 claims description 2
- 239000003149 muscarinic antagonist Substances 0.000 claims description 2
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims description 2
- GECBBEABIDMGGL-RTBURBONSA-N nabilone Chemical compound C1C(=O)CC[C@H]2C(C)(C)OC3=CC(C(C)(C)CCCCCC)=CC(O)=C3[C@@H]21 GECBBEABIDMGGL-RTBURBONSA-N 0.000 claims description 2
- 229960002967 nabilone Drugs 0.000 claims description 2
- 230000004770 neurodegeneration Effects 0.000 claims description 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 2
- 235000020824 obesity Nutrition 0.000 claims description 2
- 229940127240 opiate Drugs 0.000 claims description 2
- 229960001057 paliperidone Drugs 0.000 claims description 2
- 208000019906 panic disease Diseases 0.000 claims description 2
- 239000004031 partial agonist Substances 0.000 claims description 2
- 230000002093 peripheral effect Effects 0.000 claims description 2
- 208000028173 post-traumatic stress disease Diseases 0.000 claims description 2
- 229960003111 prochlorperazine Drugs 0.000 claims description 2
- WIKYUJGCLQQFNW-UHFFFAOYSA-N prochlorperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 WIKYUJGCLQQFNW-UHFFFAOYSA-N 0.000 claims description 2
- 229940002612 prodrug Drugs 0.000 claims description 2
- 239000000651 prodrug Substances 0.000 claims description 2
- 229960003910 promethazine Drugs 0.000 claims description 2
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 claims description 2
- 229960004431 quetiapine Drugs 0.000 claims description 2
- SBYHFKPVCBCYGV-UHFFFAOYSA-N quinuclidine Chemical compound C1CC2CCN1CC2 SBYHFKPVCBCYGV-UHFFFAOYSA-N 0.000 claims description 2
- 230000005855 radiation Effects 0.000 claims description 2
- RUOKEQAAGRXIBM-GFCCVEGCSA-N rasagiline Chemical compound C1=CC=C2[C@H](NCC#C)CCC2=C1 RUOKEQAAGRXIBM-GFCCVEGCSA-N 0.000 claims description 2
- 229960000245 rasagiline Drugs 0.000 claims description 2
- GZSKEXSLDPEFPT-IINYFYTJSA-N renzapride Chemical compound COC1=CC(N)=C(Cl)C=C1C(=O)N[C@H]1[C@H](C2)CCC[N@]2CC1 GZSKEXSLDPEFPT-IINYFYTJSA-N 0.000 claims description 2
- 229950003039 renzapride Drugs 0.000 claims description 2
- 230000000241 respiratory effect Effects 0.000 claims description 2
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 claims description 2
- 229960001534 risperidone Drugs 0.000 claims description 2
- 201000004700 rosacea Diseases 0.000 claims description 2
- KFQYTPMOWPVWEJ-INIZCTEOSA-N rotigotine Chemical compound CCCN([C@@H]1CC2=CC=CC(O)=C2CC1)CCC1=CC=CS1 KFQYTPMOWPVWEJ-INIZCTEOSA-N 0.000 claims description 2
- 229960003179 rotigotine Drugs 0.000 claims description 2
- NEMGRZFTLSKBAP-LBPRGKRZSA-N safinamide Chemical compound C1=CC(CN[C@@H](C)C(N)=O)=CC=C1OCC1=CC=CC(F)=C1 NEMGRZFTLSKBAP-LBPRGKRZSA-N 0.000 claims description 2
- 229950002652 safinamide Drugs 0.000 claims description 2
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 claims description 2
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 claims description 2
- 239000003369 serotonin 5-HT3 receptor antagonist Substances 0.000 claims description 2
- 229910000077 silane Inorganic materials 0.000 claims description 2
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 claims description 2
- 239000012453 solvate Substances 0.000 claims description 2
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical class C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 claims description 2
- 201000009032 substance abuse Diseases 0.000 claims description 2
- 231100000736 substance abuse Toxicity 0.000 claims description 2
- 208000011117 substance-related disease Diseases 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- IKBKZGMPCYNSLU-RGVLZGJSSA-N tegaserod Chemical compound C1=C(OC)C=C2C(/C=N/NC(=N)NCCCCC)=CNC2=C1 IKBKZGMPCYNSLU-RGVLZGJSSA-N 0.000 claims description 2
- 229960002876 tegaserod Drugs 0.000 claims description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 2
- 239000003029 tricyclic antidepressant agent Substances 0.000 claims description 2
- 229960003688 tropisetron Drugs 0.000 claims description 2
- ZNRGQMMCGHDTEI-ITGUQSILSA-N tropisetron Chemical compound C1=CC=C2C(C(=O)O[C@H]3C[C@H]4CC[C@@H](C3)N4C)=CNC2=C1 ZNRGQMMCGHDTEI-ITGUQSILSA-N 0.000 claims description 2
- 229940102566 valproate Drugs 0.000 claims description 2
- MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 claims description 2
- 229960000607 ziprasidone Drugs 0.000 claims description 2
- 230000001078 anti-cholinergic effect Effects 0.000 claims 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 230000036471 bradycardia Effects 0.000 description 1
- 208000006218 bradycardia Diseases 0.000 description 1
- MZDOIJOUFRQXHC-UHFFFAOYSA-N dimenhydrinate Chemical compound O=C1N(C)C(=O)N(C)C2=NC(Cl)=N[C]21.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 MZDOIJOUFRQXHC-UHFFFAOYSA-N 0.000 description 1
- 229960004993 dimenhydrinate Drugs 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- NTHPAPBPFQJABD-LLVKDONJSA-N ramosetron Chemical compound C12=CC=CC=C2N(C)C=C1C(=O)[C@H]1CC(NC=N2)=C2CC1 NTHPAPBPFQJABD-LLVKDONJSA-N 0.000 description 1
- 229950001588 ramosetron Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5701408P | 2008-05-29 | 2008-05-29 | |
| US61/057,014 | 2008-05-29 | ||
| PCT/US2009/045484 WO2009155054A2 (en) | 2008-05-29 | 2009-05-28 | 5-ht3 receptor modulators, methods of making, and use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011521963A JP2011521963A (ja) | 2011-07-28 |
| JP2011521963A5 true JP2011521963A5 (enExample) | 2012-06-14 |
| JP5465241B2 JP5465241B2 (ja) | 2014-04-09 |
Family
ID=41380582
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011511820A Active JP5465241B2 (ja) | 2008-05-29 | 2009-05-28 | ５−ｈｔ３受容体調節物質ならびにその作製方法および使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US8124600B2 (enExample) |
| EP (1) | EP2310019A4 (enExample) |
| JP (1) | JP5465241B2 (enExample) |
| KR (1) | KR101653707B1 (enExample) |
| CN (1) | CN102046176B (enExample) |
| AU (1) | AU2009260469B2 (enExample) |
| BR (1) | BRPI0913188A2 (enExample) |
| CA (1) | CA2724449C (enExample) |
| IL (1) | IL208939A (enExample) |
| MX (1) | MX2010012807A (enExample) |
| NZ (1) | NZ588715A (enExample) |
| WO (1) | WO2009155054A2 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101528225B (zh) * | 2006-08-07 | 2013-07-17 | 阿尔巴尼分子研究公司 | 作为5ht3调节剂的2-氨基苯并噁唑羧酰胺 |
| JP5663572B2 (ja) * | 2009-07-14 | 2015-02-04 | アルバニー モレキュラー リサーチ， インコーポレイテッド | ５−ｈｔ３受容体モジュレーター、その作製方法、およびその使用 |
| AU2011291506B2 (en) | 2010-08-19 | 2016-07-28 | Buck Institute For Age Research | Methods of treating mild cognitive impairment (mci) and related disorders |
| WO2012109446A1 (en) * | 2011-02-09 | 2012-08-16 | Andrew, Llc | System and method for location boosting using proximity information |
| US20150165045A1 (en) * | 2012-07-06 | 2015-06-18 | Pharmathen S.A. | Stable injectable pharmaceutical composition of neurokinin 1 receptor antagonist and process for preparation thereof |
| JOP20130213B1 (ar) | 2012-07-17 | 2021-08-17 | Takeda Pharmaceuticals Co | معارضات لمستقبلht3-5 |
| WO2014114734A1 (en) * | 2013-01-25 | 2014-07-31 | Universitat De Barcelona | Method for predicting the onset of extrapyramidal symptoms (eps) induced by an antipsychotic-based treatment |
| CN106795172B (zh) * | 2014-09-29 | 2020-07-28 | 武田药品工业株式会社 | 1-(1-甲基-1h-吡唑-4-基)-n-((1r,5s,7s)-9-甲基-3-氧杂-9-氮杂双环[3.3.1]壬-7-基)-1h-吲哚-3-甲酰胺的晶型 |
| CN107233351A (zh) * | 2017-06-07 | 2017-10-10 | 新乡医学院 | 一种治疗阿尔海默式综合症的药物组合物及应用 |
| EP3856172A4 (en) * | 2018-09-28 | 2022-10-05 | Visceral Therapeutics Inc. | PHARMACEUTICALLY ACTIVE CANNABIS-BASED COMPOSITIONS AND METHODS FOR USE IN THE TREATMENT OF GASTROINTESTINAL CONDITIONS |
| CN111825702A (zh) * | 2019-04-22 | 2020-10-27 | 成都科岭源医药技术有限公司 | 一种氮杂*并吲唑类衍生物及其制备方法和用途 |
| CN112390799B (zh) * | 2019-08-16 | 2022-04-29 | 科岭源生物科技(深圳)有限公司 | 一种含氮杂环类5-ht3受体调节剂及其制备方法和用途 |
| JP2023520164A (ja) * | 2020-03-16 | 2023-05-16 | チョンドゥー サイマウント ファーマテック カンパニー リミテッド | ５－ｈｔ３受容体モジュレーター、結晶形態、それらの製造方法及び使用 |
| WO2022110052A1 (zh) * | 2020-11-27 | 2022-06-02 | 科岭源生物科技(深圳)有限公司 | 一种含氮杂环类5-ht3受体调节剂及其制备方法和用途 |
| CA3176091C (en) * | 2020-12-31 | 2023-07-25 | 1280225 B.C. Ltd. | Method of synthesizing indole compounds |
| CN116173039B (zh) * | 2021-11-26 | 2024-05-24 | 科岭源生物科技(深圳)有限公司 | 一种治疗肠易激综合征的药物组合物及其制备方法 |
| CN117105958B (zh) * | 2022-05-24 | 2025-08-29 | 科岭源生物科技(深圳)有限公司 | 一种制备5-ht3受体调节剂的方法 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4910193A (en) * | 1985-12-16 | 1990-03-20 | Sandoz Ltd. | Treatment of gastrointestinal disorders |
| DE3810552A1 (de) * | 1988-03-29 | 1989-10-19 | Sandoz Ag | Ester und amide von indol-, benzo(b)thiopen-, benzo(b)furancarbonsaeuren oder 4-amino-2-methoxy-benzolsaeuren mit n-heterocyclischen oder n-heterobicyclischen alkoholen oder aminen, verfahren zu deren herstellung sie enthaltende pharmazeutische zusammensetzungen sowie applikator zur verabreichung derselben |
| AU7618991A (en) | 1990-05-14 | 1991-11-14 | Syntex (U.S.A.) Inc. | Novel tricyclic compounds |
| DE4125292A1 (de) * | 1991-07-31 | 1993-02-04 | Kali Chemie Pharma Gmbh | 6-oxo-azepinoindol-verbindungen sowie verfahren und zwischenprodukte zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
| US5756514A (en) * | 1996-08-22 | 1998-05-26 | Larijani; Ghassem E. | Methods for treatment and prevention of drug-induced pruritus with serotonin type 3 receptor antagonists |
| CA2332239A1 (en) | 1998-05-15 | 1999-11-25 | Guilford Pharmaceuticals Inc. | Fused tricyclic compounds which inhibit parp activity |
| US6380193B1 (en) | 1998-05-15 | 2002-04-30 | Guilford Pharmaceuticals Inc. | Fused tricyclic compounds, methods and compositions for inhibiting PARP activity |
| MXPA03004832A (es) | 2000-12-01 | 2004-05-04 | Guilford Pharm Inc | Compuestos y sus usos. |
| CA2447156A1 (en) * | 2001-06-01 | 2002-12-12 | Alcon, Inc. | Novel fused indazoles and indoles and their use for the treatment of glaucoma |
| US6770655B2 (en) | 2002-01-18 | 2004-08-03 | Aryx Therapeutics | 5-HT3 receptor antagonists and methods of use |
| US6906096B2 (en) | 2002-06-28 | 2005-06-14 | Irm Llc | 4,7-Disubstituted indoles and methods of making |
| EP1638560A1 (en) * | 2003-06-20 | 2006-03-29 | Eli Lilly And Company | 3-aminopiperidines and 3-aminoquinuclidines as inhibitors of monoamine uptake |
| JP2007510708A (ja) | 2003-11-06 | 2007-04-26 | ファイザー・プロダクツ・インク | 癌の治療における選択的ｅｒｂＢ２阻害剤／抗ｅｒｂＢ抗体の組合せ |
| GB0328900D0 (en) * | 2003-12-12 | 2004-01-14 | Glaxo Group Ltd | Novel compounds |
| KR20050062940A (ko) | 2003-12-19 | 2005-06-28 | 주식회사 엘지생명과학 | 디이소프로필((1-((2-아미노-6-할로-9ｈ-퓨린-9-일)메틸)사이클로프로필)옥시)-메틸포스포네이트의 새로운 제조방법 |
| US7910621B2 (en) | 2004-03-22 | 2011-03-22 | The Regents Of The University Of Michigan | Small molecule antagonists of XIAP family proteins |
| WO2006028161A1 (ja) * | 2004-09-09 | 2006-03-16 | Research Foundation Itsuu Laboratory | セロトニン５－ｈｔ３受容体作動薬 |
| RU2007134414A (ru) | 2005-02-17 | 2009-03-27 | Амр Текнолоджи, Инк. (Us) | Бензоксазолкарбоксамиды для лечения индуцированной химиотерапией тошноты и рвоты (cini) и синдрома раздраженного кишечника с преобладанием диареи (ibs-d) |
| AU2006279034A1 (en) * | 2005-08-05 | 2007-02-15 | Astrazeneca Ab | Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators |
| WO2007098418A1 (en) | 2006-02-17 | 2007-08-30 | Memory Pharmaceuticals Corporation | Compounds having 5-ht6 receptor affinity |
| RU2318818C1 (ru) | 2006-04-12 | 2008-03-10 | Общество С Ограниченной Ответственностью "Исследовательский Институт Химического Разнообразия" | Азагетероциклы, комбинаторная библиотека, фокусированная библиотека, фармацевтическая композиция и способ получения (варианты) |
| US20070259933A1 (en) | 2006-05-04 | 2007-11-08 | Xenoport, Inc. | Compositions, dosage forms and methods of treating emesis |
| US7553846B2 (en) | 2006-08-07 | 2009-06-30 | Albany Molecular Research, Inc. | 2-alkylbenzoxazole carboxamides as 5-HT3 modulators |
| CN101528225B (zh) | 2006-08-07 | 2013-07-17 | 阿尔巴尼分子研究公司 | 作为5ht3调节剂的2-氨基苯并噁唑羧酰胺 |
| JP2010520917A (ja) | 2007-03-13 | 2010-06-17 | ビオヴィトルム・アクチボラゲット（プブリクト） | 肥満治療用三環式イソキノリン誘導体 |
| JP5663572B2 (ja) | 2009-07-14 | 2015-02-04 | アルバニー モレキュラー リサーチ， インコーポレイテッド | ５−ｈｔ３受容体モジュレーター、その作製方法、およびその使用 |
-
2009
- 2009-05-28 BR BRPI0913188A patent/BRPI0913188A2/pt not_active IP Right Cessation
- 2009-05-28 US US12/473,940 patent/US8124600B2/en active Active
- 2009-05-28 CA CA2724449A patent/CA2724449C/en active Active
- 2009-05-28 MX MX2010012807A patent/MX2010012807A/es active IP Right Grant
- 2009-05-28 WO PCT/US2009/045484 patent/WO2009155054A2/en not_active Ceased
- 2009-05-28 EP EP09767365A patent/EP2310019A4/en not_active Withdrawn
- 2009-05-28 JP JP2011511820A patent/JP5465241B2/ja active Active
- 2009-05-28 AU AU2009260469A patent/AU2009260469B2/en active Active
- 2009-05-28 NZ NZ588715A patent/NZ588715A/xx unknown
- 2009-05-28 CN CN2009801197635A patent/CN102046176B/zh active Active
- 2009-05-28 KR KR1020107027050A patent/KR101653707B1/ko active Active
-
2010
- 2010-10-26 IL IL208939A patent/IL208939A/en active IP Right Grant
-
2012
- 2012-02-14 US US13/372,967 patent/US8501729B2/en active Active
-
2013
- 2013-07-12 US US13/941,304 patent/US8710047B2/en active Active - Reinstated
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008519794A5 (enExample) | ||
| JP2012526736A5 (enExample) | ||
| AU2009260469B2 (en) | 5-HT3 receptor modulators, methods of making, and use thereof | |
| HRP20161708T1 (hr) | Supstituirani 4-fenil-piridini za terapiju bolesti povezanih sa nk-1 receptorom | |
| JP2014505696A5 (enExample) | ||
| JP2014513140A5 (enExample) | ||
| RU2015108933A (ru) | 3-АМИНОЦИКЛОАЛКИЛЬНЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ ROBгаммаT И ИХ ПРИМЕНЕНИЯ | |
| PE20200016A1 (es) | Imidazopirimidinas diazabiciclicas sustituidas y su uso para el tratamiento de trastornos respiratorios | |
| JP2012521994A5 (enExample) | ||
| WO2009093209A3 (ru) | 2-AЛKИЛAMИHO-3-APИЛCУЛЬФOHИЛ-ЦИKЛOAЛKAHO [e ИЛИ d] ПИPAЗOЛO [1,5-a] ПИPИMИДИHЫ - АНТАГОНИСТЫ СЕРОТОНИНОВЫХ 5-HT6 РЕЦЕПТОРОВ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ | |
| RU2014105624A (ru) | Соединения индазола, способ их применения и фармацевтическая композиция | |
| HRP20201539T1 (hr) | Pozitivni alosterni modulatori muskarinskog m1 receptora | |
| CA2695742A1 (en) | Bicyclic amides for enhancing glutamatergic synaptic responses | |
| NZ605486A (en) | Spiro-cyclic amine derivatives as s1p modulators | |
| JP2013533286A5 (enExample) | ||
| MX2009008527A (es) | Compuestos de amonio cuaternario y difenilmetilo utiles como antagonistas del receptor muscarinico. | |
| JP2012523437A5 (enExample) | ||
| AU2016340798A1 (en) | Aminoisoxazoline compounds as agonists of alpha7-nicotinic acetylcholine receptors | |
| JP2010535858A5 (enExample) | ||
| JP2016028076A5 (enExample) | ||
| IL204064A (en) | Compounds 4-Formylphiprazine-1-Carboxamidine Efficacy as Muscarinic Receptor Antagonists | |
| EA201001645A1 (ru) | Хинуклидиновые производные в качестве антагонистов мускаринового м3 рецептора | |
| WO2013042135A8 (en) | Heteroaryl compounds as 5-ht4 receptor ligands | |
| MX2009009141A (es) | Formas cristalinas de un compuesto de 8-azabiciclo[3,2,1]octano. | |
| KR20190026003A (ko) | 중수소화 덱스트로메토르판의 합성 방법 |